Introduction
The annual number of unrelated hematopoietic stem cell transplantations (HSCT) worldwide exceeds 10 000, and the number is rapidly increasing. For many of these transplants, if not the majority, the patient is enrolled on a research transplant protocol. World Marrow Donor Association (WMDA) acknowledges the importance of clinical research in advancing the field of HSCT and, at the same time, the importance of having processes in place to ensure that donor rights and welfare are protected. In addition, WMDA recognizes the need for such processes to be streamlined so that they do not hinder the care of the patient or pose an undue burden to conducting research.
Because the donor is a key participant in unrelated HSCT, it is important to distinguish on which of these research transplant protocols the donor would also be considered a research subject. Determining when a donor is a research subject on their patient's research protocol is not straightforward, because most research protocols combine therapeutic activities with research activities. Consequently, it is useful to distinguish between a donor's participation in the treatment aspects of a protocol and a donor's participation in the research aspects, that is, as a research subject. In most instances, only the patient will be participating in the research activities of the protocol with the donor participating only in its treatment aspects.
Ethical and legal [1] [2] [3] as well as medical [4] [5] issues related to the donor and the donation have been previously discussed by WMDA. WMDA keeps the rights, integrity, health and well-being of all donors in focus, and develops standards accordingly. These aspects are particularly important when research protocols are to be used because a series of basic ethical and medical premises must be applied, and national and international regulations concerning research must be followed. Protocols that include the donor as a research subject can be especially difficult to administer when the donor and patient reside in different countries with different national regulations. Because there is an increasing need and demand for enrolling patients and/or donors in research protocols to learn how to improve clinical outcome of unrelated HSCT, these aspects become increasingly frequent and important.
Interests of the donor
The principles of autonomy and integrity, written informed consent, permission to withdraw, obligations, commitment and eligibility are vital to a successful unrelated transplant program. [1] [2] [3] [4] [5] The World Medical Association has further developed standards and guidelines for maintaining donors' rights and integrity whenever a research protocol is applied. These guidelines and standards are consistent with the Declaration of Helsinki Principles. 6 Although the Declaration of Helsinki Principles is written with patients in mind, the principles are applicable to volunteer, healthy donors who are included in research protocols.
Translated from the Declaration of Helsinki Principles, the health and well-being of the donor is the priority principle on the donor's side of transplantation. This principle takes precedence over the interests of science and society. In addition, the ethical principles described in the Declaration of Helsinki Principles underscore the ethical principles that apply to all stem cell donations; that is, those of respect for persons, autonomy, informed consent and the voluntary nature of participation. The situation of volunteer donors is different from many other research subjects because they are being asked to donate stem cells for a patient who is known to have a life-threatening disease. If they are asked to participate in research as part of the donation, they may not feel the same freedom to decline to participate in research as they would otherwise. It is therefore imperative that donors are presented with the research information in as noncoercive a manner as possible. Also, the donor can never take a personal profit from the research. His or her 'benefit' is altruism and a benefit for the community.
The Declaration of Helsinki Principles further states that the design and performance of each research procedure involving human subjects should be clearly formulated in a research protocol. When the HSCT takes place under a research protocol, the donor would only be considered a research subject if he/she is being asked to participate in the research activities of the protocol and not solely the therapeutic activities of the protocol. If the donor is regarded as a research subject, he or she is entitled to comprehensive information about the research protocol and the right to decline to participate in the research.
Finally, WMDA has previously determined that the donor has the right to know what is happening to the collected blood samples or cell products provided. 2, 3 This is particularly important if the samples or products are to be used in other ways than for the standard management of the patient. This is reflected in the prescription and verification forms, where a disclaimer states that the cell products collected from a donor are intended solely for the purpose of therapeutic treatment for a patient, and no other uses of these cells are permissible. In addition, biobank laws of individual countries frequently also regulate the usage of human blood or cells, particularly when samples or products are shipped abroad. Therefore, usage of donor blood or cells other than directly related to donor selection and patient treatment must be approved for research use according to the national regulations in the country where the donor resides and where required, consent obtained from the donor.
When is the donor a research subject?
Because being a research subject has important ethical, legal and practical implications, it is important to understand when the donor is a research subject. For this reason, WMDA has adopted criteria for determining when the donor is a human research subject. These criteria are based on the statement in A.1 of the Declaration of Helsinki Principles, 'Medical research involving human subjects includes research on identifiable human material or identifiable data'.
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WMDA criteria for donors as human research subjects A donor is considered a human research subject if (1) there is an intervention or interaction with the donor for research purposes; or (2) the donor's individually identifiable research material or data will be included in the research (even though material and data must be coded, a link exists to the donor's identity through the donor's Donor Center (DC)/Registry and is therefore identifiable).
The above criteria include data or materials that were collected for research purposes only. It does not include data that are routinely provided to the DC/Registry with every donation, such as donor sex, age, ethnicity, standard infectious disease marker analyses and HLA types. It also does not include cells that were collected for therapeutic activities in the protocol, even when the transplant protocol is a research protocol on the patient side. An important caveat to this is that if a research protocol requires that the stem cell collection procedure be altered in any way, then the stem cell collection procedure is now a research activity and the donor is a research subject. For example, this would include collections requiring higher than normal cell counts due to the requirements of the research.
Donors should not be considered research subjects just by virtue of donating stem cells for a patient who is being transplanted on a research protocol. Research protocols should be carefully analyzed to determine if the protocol includes donor activities that meet the criteria listed above for considering the donor to be a human research subject. On the basis of these criteria, in the vast majority of HSCT research protocols the donor would not be considered a research subject if his/her only involvement in the protocol was to donate the cells for the transplant. Flow charts, such as the one shown in Figure 1 , can be helpful in determining if the donor is participating in the research activities.
The usage of a donor blood sample for nonidentifiable research analyses falls outside the above-mentioned criteria for when a donor is a research subject. However, individual country regulations may require that a DC/Registry applies for permission as to whether a donor can be asked to consent-on a general basis-to nonidentifiable research analyses.
Donor is a research subject
Each country has its own definition and set of regulations that govern human subject protection in research. If there is a discrepancy between the national regulations in the donor's country and patient's country in assessing whether a donor is involved in research activities, the national regulations in the donor's country should always take precedence over the regulations in the patient's country. When a Transplant Center (TC) or a Registry is requesting a donation where the donor is considered a research subject by the WMDA criteria listed above, or the donor is considered a research subject by their own national regulations, the requesting TC/Registry should inform the donor's DC or Registry as soon as possible and provide at least a summary of the transplant protocol to the donor's DC/Registry. The DC/Registry can then determine if the donor is considered a research subject by their national regulations and guidelines. It is important to start this process as early as possible in the search for a donor because obtaining permissions on the donor's side may be time consuming.
If the requesting TC/Registry defines the donor as a research subject by WMDA criteria or by their national regulations, but the DC/Registry does not, it is still recommended that the donor is informed about the nature of the protocol. In addition, if the TC/Registry also requires a written informed consent from the donor, the donor should be asked to sign a consent form provided by the TC/Registry (and translated, revised and kept anonymous by the donor's DC/Registry).
If the donor is considered a research subject by regulations in the donor's country, then the study must be reviewed and approved according to that country's process. The TC will be required to provide all relevant documentation for the DC/Registry to submit the study to their Medical Review Board (MRB), Ethics Review Committee (ERC) or similar. Donors will not be allowed to donate (as a research subject) until MRB/ERC approval has been obtained and the donor signed a consent form to participate in the study.
Because it could take time to get approval for a donor's participation in a research protocol, efforts should be taken to generate formal collaborations between DC/Registries that will allow them to accept the MRB/EC approval from other Registries, or to make agreements between Registries to proactively put research protocols through their MRB/ ERC so they are approved at the time the first donor request is made. If these types of collaborations or agreements are made, it is important to make sure that the selection of the best donor for the patient is in no way compromised by the TC making it a priority to select a Donor is not a research subject.
Activity is not research. Donor is not a research subject.
The research does not involve obtaining any research related data or material (e.g., cells) from the donor or an intervention with the donor specific to the research protocol.
Recipient research does not impact donor. DC/Registry does not need to be informed of recipient's research activity.
No Yes Yes
No Donor is a research subject.
Activity is research involving donors as human subjects. Inform DC/Registry. Donor must be given information about the research protocol and provide informed consent to participate. The DC/Registry will determine if the protocol must be reviewed by their national regulatory process Activity is research.
Does the research activity involve obtaining individually identifiable donor data or donor material (e.g., cells) that will be used as part of the research?
(This includes obtaining data or cells either through an intervention or interaction with the donor specifically for research purposes).
Is the activity research?
(A systematic investigation that is clearly formulated in an experimental protocol and designed to develop or contribute to generalizable knowledge?) Figure 1 Is the donor a human research subject or a third party in research? Algorithm based on WMDA criteria.
Donors as research subjects RJ King et al donor from a Registry that has already approved the research protocol. If there is not enough time to obtain approval from the local MRB/ERC, or approval cannot be granted, alternative approaches may be considered. In such instances, the regulations in many countries could for instance allow the donor to donate stem cells by standard means, without providing additional material for research purposes. If such a donor is still chosen by the TC, the TC would then transplant the patient without inclusion of patient and donor in the research protocol.
For a related donor, the same principles of autonomy and integrity, written informed consent, permission to withdraw, obligations, commitment and eligibility discussed above are applicable. However, the logistics are quite different, for instance because the donor and patient know each other and usually reside in the same country, and because donor counseling and medical health examination frequently are performed by the patient's TC or its Collection Center. In these cases, approval of all aspects of the research protocol, including donor and patient issues, would already be in place by the participating TCs, and the donor can therefore immediately be addressed regarding the research aspects of the donation. Finally, the WMDA recommends 7 that the care of the donor is separate from that of the patient (if they are in the same institution) to avoid any possibility of coercion. The practitioner (for example, independent advocate, physician) counseling the donor should have a documented donor advocacy role and should not be involved in the recipient's care.
What if the donor or the DC/Registry declines to participate in the research?
The donor will be asked to donate for a patient in need of an unrelated donor HSCT and will also be asked to participate in research. If the donor declines to participate in the research but is willing to donate, the TC will be asked whether the transplant can be performed outside of a research protocol, for example, a standard HSCT that is not a research protocol. If this is the case, no additional approvals or consent from the donor are required.
When the donor is not a research subject but the patient is a research subject As mentioned above, most research transplant protocols involving the patient will not include research activities that involve the donor, for example, a protocol on testing a new antifungal treatment of post transplant infections. In these cases, neither the donor nor the DC/Registry need to be informed about the protocol, and the workup, donor clearance and donation should proceed without additional concerns regarding the patient's involvement in research.
Summary
Research involving human subjects is critical to improving outcomes for recipients of HSCT and for improving the donation process for unrelated stem cell donors. WMDA calls on Registries to actively participate in research activities aimed at improving clinical outcome. Most HSCT today takes place under some research transplant protocol, but in the majority of these protocols the donor will not be regarded as a research subject. However, there will be instances where a donor is a research subject. Therefore, WMDA recommends that individual registries establish procedures for efficient handling of such kinds of donation requests to support worldwide research activities and to ensure timely donation of high-quality hematopoietic stem cells for all patients in need of an unrelated donor.
